Theralase Technologies (OTCMKTS:TLTFF, CVE:TLT) has received approval from the US Food & Drugs Administration (FDA) for its next generation therapeutic laser system.
The company’s new TLC-2000 system, to provide temporary relief of pain from knee disorders, can now immediately be marketed in the United States as a result.
Roger Dumoulin-White, Theralase chief executive, says the approval represent the first of four major strategic objectives currently pursued by company by year end.
The other objectives are to secure approval for TLC-2000 in Canada, review ethics board approval for a Phase 1b trial for its anti-cancer technology to treat Non-Muscle Invasive Bladder Cancer (NMIBC), and Health Canada approval to start the NMIBC trial.